Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
GMP compliant Cell therapy CDMO
Advent Bioservices is a contract development and manufacturing organisation specialising in cell and gene therapy, operating GMP-certified facilities at Sawston, Cambridgeshire. The company offers process development, GMP manufacturing, quality control, and ultra-cold cryogenic storage services to biotech and drug…
RNA trans-splicing gene therapies for aggressive cancers
Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…
Immune cell separation and expansion platform for cell therapies
CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…
Non-viral gene therapy platform enabling durable nuclear DNA delivery
Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines…
RNA-based gene control systems for safer cell and gene therapies
Concinnity Genetics is a biotechnology company developing RNA-based control systems that enable precise regulation of gene therapies after administration. Its technology allows therapeutic gene expression to be modulated or reduced in response to side effects or clinical need, addressing a fundamental safety…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
Private umbilical cord blood and tissue stem cell banking service
Future Health Biobank is the UK's largest private stem cell bank, providing collection, processing, and long-term cryogenic storage of umbilical cord blood and cord tissue for families. Operating from an HTA- and MHRA-licensed laboratory in Nottingham, the company performs in-house PCR, serology, and flow cytometry…
Historical gene therapy platform targeting cancer stem cells
Cellinta was a University of Edinburgh-linked biotechnology company established to develop selective gene therapies targeting cancer stem cells in solid tumours. Its approach used stem-cell-specific regulatory sequences to restrict therapeutic gene expression to tumour-driving cell populations. The technology…
End-to-end viral vector design, production and gene delivery
VectorBuilder is a global provider of gene delivery solutions offering an integrated suite of research products, custom services, and clinical-grade manufacturing. The company's platform spans viral vector design and cloning, packaging of lentiviral, AAV, and adenoviral vectors, plasmid and IVT mRNA manufacture,…
Individualised neoantigen-based cell therapies for ovarian and solid cancers
Singula Bio is a seed-stage biotechnology company developing individualised, neoantigen-based cell therapies for patients with solid tumours, with an initial focus on ovarian cancer and other difficult-to-treat malignancies. The company's approach harnesses a patient's own immune system to target mutations that appear…
Cell and gene therapy CDMO with integrated consultancy services
eXmoor Pharma is a Bristol-based contract development and manufacturing organisation specialising in cell and gene therapies. Operating from a 65,000 sq ft MHRA-licensed GMP facility, the company provides services spanning process development, viral vector and cell therapy manufacture, fill and finish, and QP release.…
Oncolytic vaccinia virus platform targeting refractory solid tumours
VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour…
Biomimetic cell culture platform for reproducible cell therapy development
Stembond Technologies is a Cambridge University spin-out developing a synthetic, mechanically tuned biomimetic substrate that replicates the physical properties of human tissue microenvironments. The platform delivers reproducible cell culture conditions, reducing phenotypic drift and improving consistency across…
Global cell and gene therapy CDMO
Minaris Advanced Therapies is a company providing contract development, manufacturing and testing services across the cell and gene therapy lifecycle. Its UK operations originate from the former Oxgene business, contributing proprietary AAV and lentiviral manufacturing technologies. In December 2025 the company…
Longer-lasting RNA medicines and immune-stealthed CAR-T research
Cambridge RNA Technologies develops experimental RNA platforms intended to extend the duration of therapeutic gene expression. Its research includes technologies for longer-lasting RNA medicines. In collaboration with Anglia Ruskin University, the company has investigated immune-stealth approaches for donor-derived…
CRISPR-engineered tumour-infiltrating lymphocyte therapy
Intima Bioscience is a clinical-stage biotechnology company developing CRISPR gene-edited tumour-infiltrating lymphocyte therapies for solid tumours. Its platform targets CISH, an intracellular immune checkpoint that suppresses T cell activity against tumours; CRISPR knockout of CISH in patient-derived TILs enhances…
AAV gene therapy company targeting inherited and common retinal diseases
Beacon Therapeutics is a clinical-stage UK biopharma company developing adeno-associated virus (AAV) gene therapies for retinal diseases causing blindness. Its lead programme, laru-zova (AGTC-501), is in Phase II/III clinical trials for X-linked retinitis pigmentosa. The pipeline also includes preclinical programmes…
Stem cell therapies for equine musculoskeletal injuries
BioDivide Limited is a regenerative medicine company developing and commercialising stem cell therapies, with a current focus on equine musculoskeletal conditions. Its product uses a non-invasive proprietary method to collect and process stem cells from horses, delivering a standardised, frozen, ready-to-inject…
ML platform designing optimised CAR-T and BiTE therapies
Coding Bio is a biotechnology company using machine learning and high-throughput screening to design chimeric antigen receptor and bispecific T cell engager therapies. The company's platform screens millions of modular protein candidates in living cells to identify designs that best induce immune responses, generating…
Engineered macrophage cell therapy for inflammatory and fibrotic disease
Resolution Therapeutics is a clinical-stage biotech developing regenerative macrophage therapies for inflammatory and fibrotic diseases. Its platform harnesses the tissue-repairing properties of macrophages, engineering them to deliver anti-fibrotic and anti-inflammatory effects at sites of organ damage. The lead…